Abiopharma

🔍 West Kenneth J (Executive)

Company: HONEYWELL INTERNATIONAL INC (HON)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 403 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,535.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 215 shares of Common Stock at $239.89 per share (Direct)
  Date: 2026-07-30 | Code: F | equity_swap_involved: 0 | shares_owned_after: 2,320.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: Held in 401(k) plan | shares_owned_after: 373.86
• Sold 403 shares of Restricted Stock Units (Derivative)
  Date: 2026-07-30 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F4, F4, F3

Footnotes:

• F1: The Restricted Stock Units were granted under the 2016 Stock Incentive Plan of Honeywell International Inc. and its Affiliates and were adjusted to reflect the spin-off of Solstice Advanced Materials Inc. from Honeywell International Inc. ("Honeywell Technologies") on October 30, 2025, and further adjusted to reflect the spin-off of Honeywell Aerospace Inc. from Honeywell Technologies on June 29, 2026 and the reverse stock split of Honeywell Technologies.
• F2: Instrument converts to common stock on a one-for-one basis.
• F3: Includes the reinvestment of dividend equivalents into 46 additional restricted stock units.
• F4: The Restricted Stock Units were granted under the 2016 Stock Incentive Plan of Honeywell International Inc. and its Affiliates with all units fully vested on July 30, 2026.